» Articles » PMID: 7584137

Human T, B, Natural Killer, and Dendritic Cells Arise from a Common Bone Marrow Progenitor Cell Subset

Overview
Journal Immunity
Publisher Cell Press
Date 1995 Oct 1
PMID 7584137
Citations 151
Authors
Affiliations
Soon will be listed here.
Abstract

The early stages of lymphoid cell formation were studied by testing the differentiative potential of phenotypically defined subsets of CD34+ bone marrow cells. A subpopulation of CD34+ Lin- CD45RA+ cells expressing CD10 was isolated by flow cytometry. Such cells are CD38+, HLA-DR+, do not express significant levels of Thy-1 and c-kit, lack erythroid, myeloid, megakaryocytic potential, and give rise only to lymphoid T, B, natural killer (NK), and dendritic cells (DC) in kinetics and titration experiments. Limiting dilution analysis demonstrates the existence of multipotential B/NK/DC progenitor clones in the CD34hi Lin-CD10+ adult bone marrow cell population. Thus, nonprimitive progenitors for lymphoid cells and for DCs can be distinct from those of myeloid, megakaryocytic, and erythroid cells, implying that the DC lineage is developmentally more closely related to the lymphoid lineage than to the myeloid lineage. This study provides new insights into the organization and development of the human lympho-hematopoietic system.

Citing Articles

T Cell Development: From T-Lineage Specification to Intrathymic Maturation.

Golzari-Sorkheh M, Yoganathan K, Chen E, Singh J, Zuniga-Pflucker J Adv Exp Med Biol. 2025; 1471:81-137.

PMID: 40067585 DOI: 10.1007/978-3-031-77921-3_4.


Phenotypic Characterisation of Bone Marrow-Derived Haematopoietic Stem/Progenitor Cells from HIV-Infected Individuals.

Mistry P, Potgieter J, Pepper M, Durandt C Stem Cell Rev Rep. 2025; .

PMID: 39836357 DOI: 10.1007/s12015-024-10834-z.


Terminal deoxynucleotidyl transferase and CD84 identify human multi-potent lymphoid progenitors.

Kim Y, Calderon A, Favaro P, Glass D, Tsai A, Ho D Nat Commun. 2024; 15(1):5910.

PMID: 39003273 PMC: 11246490. DOI: 10.1038/s41467-024-49883-w.


NK Cell-Targeted Immunotherapies in Bladder Cancer: Beyond Checkpoint Inhibitors.

Wang Y, Ranti D, Bieber C, Galsky M, Bhardwaj N, Sfakianos J Bladder Cancer. 2024; 9(2):125-139.

PMID: 38993289 PMC: 11181717. DOI: 10.3233/BLC-220109.


Preclinical characterization of a novel investigational monoclonal antibody CM313 with potent CD38-positive cell killing activity.

Liu W, Yu J, Sun K, Song Q, Li Y, He Y Front Immunol. 2024; 15:1410457.

PMID: 38765013 PMC: 11099226. DOI: 10.3389/fimmu.2024.1410457.